Skip to main content

Vulvovaginal Candidiasis Update: New Treatment Options for You and Your Patients

Speaker(s)
Lucinda Farina & Christina Muzny

Speaker Bio(s)
Lucinda Farina, Ph.D., CNM, FNP, is an experienced clinician, educator, and researcher. Dr. Farina earned her midwifery certificate from Frontier Nursing University in 1999, MSN from Case Western Reserve University in 2000, Family Nurse Practitioner certificate from Case Western Reserve University in 2016, and her Ph.D. from Walden University in 2020. She holds a full-time faculty appointment at Frontier Nursing University where she enjoys working with doctoral students and chairing the Research Committee. Her research work includes the efficacy of risk reduction counseling on the acquisition of STIs at the Cleveland Department of Public Health, phase 3 clinical trial management for the product now marketed as Ella, as well as the Infant Mortality Project for Harvard University, the Maternal-Infant Interaction at the University of Rochester, and the Adult Failure to Thrive study at Case Western Reserve University. Dr. Farina serves on the Ohio Collaborative to Prevent Infant Mortality and on the Board of Directors for the Ohio ACNM Affiliate. As a clinician, Dr. Farina specializes in GYN, Sexually Transmitted Infections, and Gender Affirming Therapy.

Christina Muzny, MD, MSPH, FACP, FIDSA
Associate Professor of Medicine, Obstetrics/Gynecology, & Epidemiology
Vice Chair, UAB Institutional Review Board
Medical Director, UAB Vaginitis Clinic
Dr. Christina Muzny obtained her medical degree at the Texas A&M University Health Sciences Center College of Medicine followed by an internal medicine residency and an infectious diseases fellowship at the University of Mississippi Medical Center. She joined the ID faculty at the University of Alabama at Birmingham (UAB) in 2010. She has since obtained an MSPH in Public Health (Epidemiology) at the UAB School of Public Health. Her clinical and research interests focus on the HIV and STIs in women, specifically vaginal infections. Dr. Muzny currently has R01 and R21 funding from NIH/NIAID to study the pathogenesis of BV. She has also participated in multiple clinical trials on the treatment of trichomoniasis in women. Dr. Muzny is a tenured Associate Professor in the Division of Infectious Diseases at UAB with secondary appointments in the UAB Department of Epidemiology and Obstetrics & Gynecology. She is currently the Medical Director of the UAB Vaginitis Clinic.

Course Description
We will provide an update on acute and recurrent RVVC highlighting the challenges in treating patients with currents oral and topical azoles and provide an update on the new treatments recently approved for use in VVC.

Learning Objectives
1. The epidemiology of vulvovaginal candidiasis (VVC), including RVVC and its impact on Quality of Life measures
2. Challenging patients with suboptimal response to traditionally available oral and topical therapies
3. Current guidelines for treating acute and recurrent VVC, including resistant infections
4. New agents available for treatment of acute VVC and prevention of recurrent VVC
5. Review of new agents in the pipeline

CEUs Offered: 1 CE / 0.5 Rx

Course Expiration: October 27, 2024

This course is FREE and open to ALL